QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文 ACTA PHARMACOLOGICA SINICA, 2022 作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang 收藏  |  浏览/下载：92/0  |  提交时间：2022/03/28 HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance   YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文 BRITISH JOURNAL OF CANCER, 2020, 页码: 12 作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun 收藏  |  浏览/下载：15/0  |  提交时间：2020/12/24 DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp9O-Cdc37 interaction 期刊论文 CANCER LETTERS, 2018, 卷号: 434, 页码: 70-80 作者:  Chen, Xiangling;  Liu, Peng;  Wang, Quanren;  Li, Yun;  Fu, Li 收藏  |  浏览/下载：35/0  |  提交时间：2019/01/08 Cdc37  DCZ3112  Geldanamycin  Hsp90  HER2-positive breast cancer   Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells 期刊论文 CANCER SCIENCE, 2017, 卷号: 108, 期号: 7, 页码: 1458-1468 作者:  Wang, Hongbin;  Wang, Wenqian;  Xu, Yongping;  Yang, Yong;  Chen, Xiaoyan 收藏  |  浏览/下载：31/0  |  提交时间：2019/01/08 Antibody-drug conjugate  drug resistance  HER2  T-DM1  V-ATPase   Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 26 作者:  Wang, Chao;  Wang, Lingfei;  Yu, Xiaojie;  Zhang, Yajun;  Meng, Yanchun 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 ErbB2  gastric cancer  acquired resistance to trastuzumab  domain I- specific antibody  programmed cell death   Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 26 作者:  Wang, Chao;  Wang, Lingfei;  Yu, Xiaojie;  Zhang, Yajun;  Meng, Yanchun 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/06 ErbB2  gastric cancer  acquired resistance to trastuzumab  domain I- specific antibody  programmed cell death